Grace Therapeutics, Inc. GRCE
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -43.93%
- 1 year
- -39.18%
- Open
- 1.95
- Prev close
- 1.94
- Mkt cap
- 40.81M
- Vol
- 85.94K
- Avg vol
- 139.87K
- EPS
- -1.17
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.87
- High
- 1.98
- Forward P/E
- -2.90
- Beta
- 1.51
- Short ratio
- 3.25
- Inst. own
- 21.39%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 10, 2025
- 50-d avg
- 3.44
- 200-d avg
- 3.04
- 1y target
- 10.44
6M chart
Signals (10)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 28, 2026 | 4 days ago |
| MACD: Sell Signal | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 11, 2026 | 1 month ago |
| SMA: Bullish | Sep 10, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 14, 2026 | 2 months ago |
| RSI: Oversold | Jul 29, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 23, 2026 | 3 months ago |
| SMA: Bullish | Jul 2, 2026 | 4 months ago |
| MACD: Buy Signal | May 12, 2026 | 5 months ago |
Key statistics
- Market cap
- 37.11M
- Enterprise value
- 14.15M
- Trailing P/E
- 0.00
- Forward P/E
- -2.90
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.56
- EPS (TTM)
- -1.29
- Beta
- 1.51
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -5.58M
- Total cash
- 19.41M
- Total debt
- 0
- Return on equity
- -18.56%
- Shares outstanding
- 10.14M
- Short % of float
- 1.60%
- 50-day average
- 3.44
- 200-day average
- 3.04
Analyst view
Consensus: strong buy
- Target (low)
- 7.79
- Target (mean)
- 10.44
- Target (high)
- 12.30
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 10, 2025
Expected Feb 10, 2025. Consensus EPS estimate -0.45333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 10, 2025 | Dec 1, 2024 | -0.27 | — | — | — |
| Nov 13, 2024 | Sep 1, 2024 | -0.33 | -0.33 | 0.00 | 0.00% |
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- acastipharma.com
News
- Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference
- Grace Therapeutics Q1 EPS $(0.91) Misses $(0.18) Estimate
- Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
- Grace Therapeutics Announces $10 Million Private Placement
- Grace Therapeutics Receives FDA Meeting Minutes From Type A Meeting; FDA Confirms No Clinical Safety Or Efficacy Deficiencies
- Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
- Grace Therapeutics (NASDAQ:GRCE) Trading Down 2.5% – Here’s What Happened
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Grace Therapeutics Q4 EPS $(0.06) Beats $(0.15) Estimate
- Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
Your note
Sign in to keep a note on GRCE — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Adar1 Capital Management, LLC | 9.46% | 959,571 | 3.51M | Sep 29, 2024 |
| AIGH Capital Management LLC | 6.32% | 641,083 | 2.35M | Sep 29, 2024 |
| Bank of America Corporation | 4.88% | 494,698 | 1.81M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.16% | 16,147 | 59.10K | Sep 29, 2024 |
| National Bank of Canada/FI | 0.03% | 2,719 | 9.95K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.03% | 2,732 | 10.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.03% | 3,058 | 11.19K | Oct 30, 2024 |